Galenica Sante AG (GALE) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Galenica Sante AG stock CHF 61.79, price CHF 89.45, that is 30.9% below the price, quality 60 out of 100. Rating: overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range CHF 57.79 – CHF 101.34 · fair‑value band CHF 46.34 – CHF 77.24 · the CHF 89.45 price screens above the CHF 61.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Galenica Sante in your weekly email
Every Wednesday you see whether Galenica Sante is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Galenica AG provides healthcare services in Switzerland and internationally.
Show moreShow less
It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice.
This segment also offers medication for treatment of patients at home; laboratory medicine, pathology and specialized personalized diagnostic services; and develops, markets, and sells healthcare services and products through various distribution channels.
The Logistics & IT segment provides various specialized pre-wholesale services, including storage, distribution, and debt collection to pharmaceutical and healthcare companies.
This segment also offers master data systems for the healthcare market; develops management solutions for the healthcare market; and publishes printed and electronic technical information on pharmaceutical products, as well as offers complete management solutions for pharmacies.
In addition, it provides on-schedule delivery services to pharmacies, drugstores, doctors, hospitals, and care homes. The company was founded in 1927 and is headquartered in Bern, Switzerland.
Stock analysis
Galenica Sante AG (GALE) currently trades at CHF 89.45, while our model-based Fair Value estimate is CHF 61.79, 31% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of CHF 79.64 per share, and 0 of the 25 models we run sit above the CHF 89.45 price.
Bear case: the Earnings-Based group reads lowest at CHF 34.74, and 25 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: CHF 46.34 (bear) to CHF 77.24 (bull), the price of CHF 89.45 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Galenica Sante AG reported revenue of CHF 4.1B in FY2025 versus CHF 3.8B in FY2021, a compound +1.9%/yr. Reported net income was CHF 181M in FY2025, compounding +1.9%/yr from FY2021.
Key figures
Market cap CHF 4.5B Mid · P/E ratio 27.7 · P/S ratio 1.04 · EPS (TTM) CHF 3.23 · Dividend yield 2.8% · Net margin 3.7% · Return on equity 11.4% · Return on assets (EBIT) 6.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 11% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at −31%, GALE screens richer than that median.
Fair Value models
BearCHF 46.34Fair Value CHF 61.79BullCHF 77.24
Price CHF 89.45 · Downside -30.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (CHF 0.6240 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.5%
Start year 2020 (pandemic). Over 10 years: +3.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+4.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.4%
Dividend (yield on the price)2.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.4% vs 8.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 5%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +3.6% a year for the price and +3.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (8 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: The integrated Swiss healthcare network provides resilience via diversified pharmacy, logistics and home-care contributions, yet it contends with regulatory pressures and typically thin distribution margins.
Main risk: Regulatory pressures in the Swiss healthcare sector threaten to compress the already thin margins of pharmaceutical wholesale and integrated logistics operations.
Galenica operates an integrated Swiss healthcare network of pharmacies, wholesale logistics, home care and a newer diagnostics segment. Growth held up in the first half even with weaker seasonal demand for cold remedies thanks to broader contributions across these areas. Our models currently see it as overvalued. Does the network effect deliver more resilience and cross-selling than regulatory pressures and thinner distribution margins take away?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Top 25%
Fair Value upside−30.9% · Bottom 25%
Profitability
Return on equity (12 months)11.4% · Top 25%
Return on assets5.4% · Top 25%
Net margin (12 months)3.7% · Above median
Operating margin (12 months)3.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)7.0% · Above median
Dividend yield (12 months)2.8% · Above median
Balance sheet
Debt / equity0.41× · Highest 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/E (12 months)27.7× · Priciest 25%
P/B3.01× · Priciest 25%
P/S (12 months)1.04× · Pricier than median
Price / free cash flow (fiscal year)16.4× · Pricier than median
EV/EBITDA19.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 38
FUTURE (revenue growth)35· sector 24
PAST (return on equity)45· sector 28
HEALTH (low debt)80· sector 97
DIVIDEND (yield)56· sector 54
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Galenica Sante AG Fair Value". https://www.fairvalue-calculator.com/stock/GALE
Frequently asked questions
Is Galenica Sante AG (GALE) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of CHF 61.79 versus a price of CHF 89.45, about 31% lower (overvalued).
What is the fair value of GALE?
Our model-based fair value for Galenica Sante AG is CHF 61.79 (as of Nov 6, 2026), built from audited fundamentals. The current price: CHF 89.45.
What is the quality score of GALE?
Galenica Sante AG has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Galenica Sante AG (GALE)?
Our model-based price target is the fair value of CHF 61.79 (as of Nov 6, 2026) from 25 valuation models. Cautious scenario CHF 46.34, optimistic scenario CHF 77.24. It is a calculation from audited fundamentals, not an analyst target.
What is the Galenica Sante AG stock forecast for 2026?
Our models put fair value at CHF 61.79, about 31% lower versus a price of CHF 89.45 (overvalued). Cautious scenario CHF 46.34, optimistic scenario CHF 77.24. The calculation is refreshed regularly with new filings.
What is the revenue of Galenica Sante AG (GALE)?
Galenica Sante AG reported trailing-twelve-month revenue of about CHF 4.3B (latest available figure, as of Nov 6, 2026).
Does Galenica Sante AG pay a dividend?
Galenica Sante AG currently shows a dividend yield of 2.79% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Galenica Sante AG (GALE) and when is the ex-dividend date?
Galenica Sante AG pays a dividend of CHF 2.50 per share a year, a dividend yield of 2.8%. The last ex-dividend date was Apr 23, 2026. A dividend has been paid every year since at least 2017. The payout ratio is 77.4% of earnings. Free cash flow covers the dividend 2.19 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Galenica Sante AG (GALE)?
For today's price to be fair in a discounted-cash-flow model, Galenica Sante AG would have to grow free cash flow by +4.2 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.5 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of GALE use?
Our models discount Galenica Sante AG at 8.3 %: a base by market capitalisation (mid), damped by beta 0.26, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Galenica Sante AG that is +4.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has Galenica Sante AG (GALE) delivered so far?
Over the past 5 years revenue at Galenica Sante AG grew +3.5 % a year. The price currently implies free-cash-flow growth of +4.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Galenica Sante AG (GALE) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Galenica Sante AG (+4.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Galenica Sante AG (GALE)?
The free-cash-flow yield on the price is 6.10 %: that much free cash flow Galenica Sante AG produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Galenica Sante AG (GALE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Galenica Sante AG it is CHF 61.79 per share (as of Nov 6, 2026), against a price of CHF 89.45. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Galenica Sante AG stock overvalued or undervalued in 2026?
As of Nov 6, 2026, GALE trades above its calculated fair value: price CHF 89.45, fair value CHF 61.79, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GALE?
No. The price is what the market pays today (CHF 89.45); the fair value is what the company's own numbers justify (CHF 61.79). For Galenica Sante AG the two are CHF 27.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is Galenica Sante AG worth?
The market values Galenica Sante AG at about CHF 4.5B (market capitalisation, as of Nov 6, 2026). Per share that is CHF 89.45; our models calculate a fair value of CHF 61.79 per share.
What do the bullish and bearish scenarios say about GALE?
Our models span a range for Galenica Sante AG: cautious scenario CHF 46.34, base CHF 61.79, optimistic CHF 77.24 per share (as of Nov 6, 2026, price CHF 89.45). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GALE?
Galenica Sante AG trades at a price-to-earnings ratio of 27.7 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 61.79 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings: 20.7. Other multiples: P/B 3.0, P/S 1.0, EV/EBITDA 19.4.
How solid is the balance sheet of Galenica Sante AG (GALE)?
Balance-sheet figures for Galenica Sante AG (as of Nov 6, 2026): return on equity 11.4%, debt of 0.41 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is GALE from its 52-week high?
Galenica Sante AG trades at CHF 89.45, about 12% below its 52-week high of CHF 101.34 and 11% above the low of CHF 80.45 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 61.79 is for.
Which stocks are comparable to Galenica Sante AG?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Galenica Sante AG stock attractive at the current price?
The data as of Nov 6, 2026: price CHF 89.45, calculated fair value CHF 61.79 (−31%), Quality Score 60/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GALE calculated?
We run Galenica Sante AG through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of CHF 61.79 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Galenica Sante AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Galenica Sante AG (GALE)?
The closing price on Nov 6, 2026 was CHF 89.45. Our model-based fair value is CHF 61.79, about 31% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Galenica Sante AG right now?
The price sits above even our optimistic bull case (CHF 77.24). The favourable scenario is already priced in. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Galenica Sante AG (GALE) come from?
Earnings per share at Galenica Sante AG grew +9.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.4 %, EBIT margin +2.8 %, tax rate +0.4 %, residual (interest, one-offs) +2.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Galenica Sante AG
How large is the market capitalisation of Galenica Sante AG (GALE)?
The market capitalisation of Galenica Sante AG is CHF 4.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Galenica Sante AG (GALE)?
The price-to-sales ratio of Galenica Sante AG is 1.04 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Galenica Sante AG (GALE)?
Earnings per share at Galenica Sante AG are CHF 3.23 (price ÷ EPS = P/E 27.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Galenica Sante AG (GALE)?
The dividend yield of Galenica Sante AG is 2.8% (payout 77.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Galenica Sante AG (GALE)?
The net margin of Galenica Sante AG is 3.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Galenica Sante AG (GALE)?
The return on equity (ROE) of Galenica Sante AG is 11.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Galenica Sante AG (GALE)?
On an EBIT basis the return on assets of Galenica Sante AG is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Galenica Sante AG (GALE)?
The operating margin of Galenica Sante AG is 3.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Galenica Sante AG (GALE)?
Revenue at Galenica Sante AG is growing +7.0% versus a year earlier (3y avg +1.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Galenica Sante AG (GALE)?
Earnings per share at Galenica Sante AG are growing −24.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Galenica Sante AG (GALE) carry?
The net debt of Galenica Sante AG is CHF 945M (fiscal year 2025, ≈ 3.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Galenica Sante AG in the live analysis
One click puts Galenica Sante AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026